6
项与 Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania) 相关的临床试验Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer
Phase 1 - Safety and Proof of Concept
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer
Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma
100 项与 Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania) 相关的临床结果
100 项与 Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania) 相关的转化医学
100 项与 Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania) 相关的专利(医药)
100 项与 Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania) 相关的药物交易